- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of lacidipine.
Treatment should be adapted to the individual response.
Initial dose 2mg once daily in the morning, increased if necessary after intervals of 3 to 4 weeks to 4mg daily, then to 6mg daily if necessary.
Doses greater than 6mg daily have not been shown to be significantly more effective.
Treatment may be continued indefinitely.
Patients with Hepatic Impairment
There may be an increased hypotensive effect in patients with hepatic impairment. Monitor these patients carefully and in severe cases consider a dose reduction.
Children under 18 years
Severe left ventricular failure
Within 1 month of a myocardial infarction
Precautions and Warnings
Cardiac conduction defects
Congenital long QT syndrome
Glucose-galactose malabsorption syndrome
Ischaemic heart disease
Poor cardiac reserve
Advise ability to drive/operate machinery may be affected by side effects
Monitor patients with hepatic impairment
Discontinue if cardiogenic shock develops
Discontinue if ischaemic pain occurs shortly after starting therapy
Advise patient to moderate alcohol intake during treatment
Grapefruit prod increase dihydropyridine Ca channel blocker bioavailability
Lacidipine has not been shown to be effective for the secondary prevention of myocardial infarction.
Lacidipine has not had safety or efficacy established in the treatment of malignant hypertension.
Lacidipine should be used with caution in patients with hepatic impairment because antihypertensive effect may be increased.
Pregnancy and Lactation
Lacidipine is contraindicated during pregnancy.
The manufacturer does not recommend using lacidipine during pregnancy unless the potential benefits for the mother outweigh the adverse effects to the foetus or neonate. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.
Lacidipine is contraindicated during breastfeeding.
The manufacturer does not recommend breastfeeding whilst using lacidipine unless the potential benefits for the mother outweigh the adverse effects to the neonate. Animal data reports lacidipine maybe excreted in breast milk, however presence in human breast milk is unknown. Effects on exposed infants are unknown.
Aggravation of angina
Increase in alkaline phosphatase
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: January 2020
Summary of Product Characteristics: Lacidipine 2mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 4mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 6mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 2mg Film-Coated Tablets. Teva UK Ltd. Revised June 2015.
Summary of Product Characteristics: Lacidipine 4mg Film-Coated Tablets. Teva UK Ltd. Revised November 2019.
Summary of Product Characteristics: Molap 4mg Film-Coated Tablets. Rivopharm UK Ltd. Revised November 2016.
Summary of Product Characteristics: Motens Tablets 2mg. GlaxoSmithKline UK. Revised June 2016.
Summary of Product Characteristics: Motens Tablets 4mg. GlaxoSmithKline UK. Revised June 2016.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 28 January 2020
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.